Protein / target

VIP peptides

Encoded byVIPP01282Homo sapiensSwiss-Prot

UniProt: P01282 Ensembl: ENSG00000146469 HGNC: HGNC:12693 NCBI Gene: 7432

Antibody-tractable

Druggability

GO CC high conf

Research papers

Protein at a glance

Biological role

Type 1 vasoactive intestinal polypeptide receptor binding

Strongest disease association

Placental abruption

Via encoding gene VIP · Genetic evidence · score 0.23

Research activity

Emerging research

3 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

View complete UniProt function annotation

VIP is a neuropeptide involved in a diverse array of physiological processes through activating the PACAP subfamily of class B1 G protein-coupled receptors: VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2) (PubMed:1318039, PubMed:36385145, PubMed:8933357). Abundantly expressed throughout the CNS and peripheral nervous systems where they primarily exert neuroprotective and immune modulatory roles (PubMed:3456568). Also causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder (PubMed:15013843)

Subcellular location

Secreted

Domains and Gene Ontology detail (18)

Gene Ontology

Cextracellular region
Cextracellular space
Cneuron projection
Fhormone activity
Fneuropeptide hormone activity
Fpeptide hormone receptor binding
Ftype 1 vasoactive intestinal polypeptide receptor binding
Ftype 2 vasoactive intestinal polypeptide receptor binding
Padenylate cyclase-activating G protein-coupled receptor signaling pathway
Pbody fluid secretion
Pepinephrine secretion
PG protein-coupled receptor signaling pathway

170 aa · 19 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOG protein-coupled signallingUniProt · GO

View supporting evidence

Cell proliferation & survival

·positive regulation of cell population proliferation

G protein-coupled signalling

·VIP is a neuropeptide involved in a diverse array of physiological processes through act…
·adenylate cyclase-activating G protein-coupled receptor signaling pathway
·G protein-coupled receptor signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene VIP

Gene-level evidence surfaced through the gene VIPthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Placental abruption

0.23Preliminary

Genetic evidence dominant · Open Targets 0.14

Alzheimer's Disease

0.13Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Carcinoma, Hepatocellular

0.12Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Neoplasms

0.12Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

COVID-19

0.11Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

View evidence synthesis (5)

Placental abruptionPreliminary

0.23

agreement 0.11–0.35

Genetic100%

Open Targets aggregate 0.14 · 1 independent evidence family

Alzheimer's DiseasePreliminary

0.13

agreement 0.00–0.40

Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

Carcinoma, HepatocellularPreliminary

0.12

agreement 0.00–0.39

Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

NeoplasmsPreliminary

0.12

agreement 0.00–0.39

Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

COVID-19Preliminary

0.11

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Placental abruption0.14

Alzheimer's Disease0.10

Carcinoma, Hepatocellular0.10

Neoplasms0.10

COVID-190.09

Neuroblastoma0.09

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)

AB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM